--- title: "FocalTherics (FOCL) Projected to Announce Quarterly Earnings on Thursday" type: "News" locale: "en" url: "https://longbridge.com/en/news/296439678.md" description: "FocalTherics (FOCL) is scheduled to release its Q2 2026 earnings before the market opens on Thursday, August 27. Analysts project an EPS of ($0.2287) and revenue of $22.48 million. Recent analyst ratings range from 'Sell' to 'Buy', with a consensus 'Hold' rating and a target price of $7.75. Additionally, insiders David R. Horn and Fran Schulz each acquired 10,000 shares on August 14, while Kovack Advisors Inc. initiated a new position in the fourth quarter." datetime: "2026-08-20T05:41:20.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296439678.md) - [en](https://longbridge.com/en/news/296439678.md) - [zh-HK](https://longbridge.com/zh-HK/news/296439678.md) generator: "portal-rs" --- # FocalTherics (FOCL) Projected to Announce Quarterly Earnings on Thursday FocalTherics (NASDAQ:FOCL - Get Free Report) is anticipated to announce its Q2 2026 results before the market opens on Thursday, August 27th. Analysts expect the company to announce earnings of ($0.2287) per share and revenue of $22.4840 million for the quarter. Investors may visit the the company's upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, August 13, 2026 at 4:30 PM ET. FocalTherics (NASDAQ:FOCL - Get Free Report) last announced its earnings results on Friday, August 14th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.19). The business had revenue of $13.20 million during the quarter. FocalTherics had a negative return on equity of 248.00% and a negative net margin of 56.26%. On average, analysts expect FocalTherics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year. ## FocalTherics Price Performance NASDAQ FOCL opened at $4.36 on Thursday. The stock's 50 day simple moving average is $5.37. FocalTherics has a one year low of $1.30 and a one year high of $6.40. The company has a market cap of $163.41 million, a price-to-earnings ratio of -4.23 and a beta of -0.04. The company has a debt-to-equity ratio of 1.79, a quick ratio of 0.99 and a current ratio of 1.60. ## Analysts Set New Price Targets A number of equities analysts have commented on FOCL shares. Piper Sandler reissued a "neutral" rating and issued a $4.00 price objective on shares of FocalTherics in a research note on Friday, August 14th. HC Wainwright restated a "buy" rating and issued a $10.00 target price on shares of FocalTherics in a research note on Tuesday, June 2nd. Mizuho set a $15.00 price target on FocalTherics and gave the company an "outperform" rating in a report on Friday, July 17th. Wall Street Zen downgraded shares of FocalTherics from a "hold" rating to a "sell" rating in a research report on Saturday, August 15th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of FocalTherics in a research report on Monday. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, FocalTherics has an average rating of "Hold" and a consensus target price of $7.75. **Read Our Latest Research Report on FOCL** ## Insider Transactions at FocalTherics In related news, Director David R. Horn acquired 10,000 shares of the company's stock in a transaction that occurred on Friday, August 14th. The stock was purchased at an average price of $4.75 per share, for a total transaction of $47,500.00. Following the transaction, the director directly owned 10,000 shares of the company's stock, valued at approximately $47,500. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Fran Schulz acquired 10,000 shares of FocalTherics stock in a transaction on Friday, August 14th. The shares were purchased at an average cost of $4.75 per share, for a total transaction of $47,500.00. Following the acquisition, the director owned 15,100 shares in the company, valued at approximately $71,725. This represents a 196.08% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased a total of 116,000 shares of company stock worth $551,000 over the last ninety days. 10.10% of the stock is currently owned by insiders. ## Hedge Funds Weigh In On FocalTherics An institutional investor recently bought a new position in FocalTherics stock. Kovack Advisors Inc. purchased a new stake in FocalTherics (NASDAQ:FOCL - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 16,000 shares of the company's stock, valued at approximately $53,000. Institutional investors own 62.74% of the company's stock. ## FocalTherics Company Profile (Get Free Report) EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications. ## See Also - Five stocks we like better than FocalTherics - Bloom Energy’s AI Surge Meets a Valuation Reality Check - Target Is Winning Shoppers Back—Can the Rally Reach $180? - IonQ’s Space Contract Points to a New Frontier for Quantum Investors - Is Apple’s AI Strategy Smarter Than Skeptics Think? *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.* Continue following MarketBeat Add MarketBeat as your preferred source on Google to see our latest stories in your feed. Add As Preferred Source ## Should You Invest $1,000 in FocalTherics Right Now? Before you consider FocalTherics, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and FocalTherics wasn't on the list. While FocalTherics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [FOCL.US](https://longbridge.com/en/quote/FOCL.US.md) - [PIPR.US](https://longbridge.com/en/quote/PIPR.US.md) - [MFG.US](https://longbridge.com/en/quote/MFG.US.md) - [8411.JP](https://longbridge.com/en/quote/8411.JP.md) - [EDAP.US](https://longbridge.com/en/quote/EDAP.US.md) - [BE.US](https://longbridge.com/en/quote/BE.US.md) - [TGT.US](https://longbridge.com/en/quote/TGT.US.md) ## Related News & Research - [FocalTherics™ Reports Second Quarter 2026 Financial Results | FOCL Stock News](https://longbridge.com/en/news/295838933.md) - [Edap TMS CFO Kenneth S. Mobeck buys 5,000 common shares for $23,750](https://longbridge.com/en/news/296088848.md) - [Bioz and Xenocs Improve Researcher Product Evaluation Through On-Page Publication Insights](https://longbridge.com/en/news/296195684.md) - [Simpar unit CS Infra buys Terra’s 49% stake in CS Mobi Leste SP](https://longbridge.com/en/news/296285820.md) - [OLOX: Q2 2026 revenue jumped 194% on crypto mining, but going concern risks and losses persist](https://longbridge.com/en/news/296392686.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**